



Contriving a novel multi-epitope subunit vaccine from *Plasmodium falciparum* vaccine candidates against malaria

Collins Ojonugwa Mamudu^{1,2†}, Franklyn Nonso Iheagwam^{1,3*†}, Esther Ogechi Okafor^{1,4}, Titilope Modupe Dokunmu^{1,2}, Olubanke Olujoke Ogunlana^{1,2}

¹Department of Biochemistry, Covenant University, Ota, Nigeria.

²Covenant Applied Informatics and Communication Africa Centre of Excellence, Ota, Nigeria.

³Covenant University Public Health and Wellbeing Research Cluster, Ota, Nigeria.

⁴Covenant University Bioinformatics Research, Ota, Nigeria.

ARTICLE HISTORY

Received on: 26/07/2023

Accepted on: 23/09/2023

Available Online: XX

Key words:

Epitopes,
immunoinformatics, malaria,
Plasmodium falciparum,
vaccine construct.

ABSTRACT

In this study, immunoinformatics strategies were used to design a subunit vaccine against malaria from immunogenic regions of three *Plasmodium falciparum* surface antigens; liver stage antigen 3-C (V750-K1433), merozoite surface antigen 180 truncate-4 (A805-P1093), and merozoite surface protein 10 region 1 (D29-N188). A multi-epitope subunit vaccine construct (VC) was designed from immunodominant B- and T-cell epitopes followed by structure prediction, evaluation, and validation. Toll-like receptors (TLRs) 2 and 4 were docked with the VC. Their complexes' molecular dynamics, immune stimulation, codon optimization, and *in silico* cloning of the VC were simulated. The VC is a 49.2 kDa antigenic and nonallergenic protein, comprised of 26% α -helix, 7% β -strand, 66% coil. The immune simulation test showed that the vaccine could provoke adaptive immune responses, and molecular docking tests showed that it interacts strongly with TLR-2 (-945.1 kcal/mol) and TLR-4 (-919.8 kcal/mol) to form complexes of high stability that hardly deform. The guanine-cytosine content and codon adaptation index of the VC were 42.94 and 0.99 after codon optimization. *Escherichia coli* pET-28a(+) was identified as the best vector for optimal gene expression. In conclusion, the study reveals that the VC shows promising results in neutralizing *falciparum* malaria.

INTRODUCTION

Malaria is a deadly tropical disease caused by an infection of the protozoan *Plasmodium*, and it continues to be the most significant human parasitic illness in the world. It is a vector-borne illness. It spreads through the bites of female Anopheles mosquitoes infected with *Plasmodium* parasites [1]. Over the last century, despite the increased research efforts and control measures to drive down the malaria burden globally, eradication strategies and interventions have only been fairly successful. The parasite has co-evolved with new interventions, and eradication remains ongoing [2]. *Plasmodium* species

have developed resistance to all known classes of antimalarial compounds and drugs which is one of the major challenges in the fight against malaria [3], in addition to inadequate research funding, healthcare professionals, facilities, research efforts in malaria-endemic regions, and limited knowledge about naturally acquired immunity to malaria [4,5].

Vaccination is an economical and successful solution to stop infectious diseases [6–10]. Advances have been made in blood-stage vaccine development, as they have reached clinical trials; however, they were unsuccessful in controlling human malaria infection on the field [11–13]. Antigen polymorphism, redundancy, parasite immune evasion, and low effectiveness of vaccine candidates have greatly hindered the rapid development of a licensed vaccine to neutralize malaria [14–18]. Furthermore, increasing insecticide resistance and asymptomatic infections have also been major setbacks [19,20], and cases of resurgence and increased malaria deaths have been

*Corresponding Author
Franklyn Nonso Iheagwam, Department of Biochemistry,
Covenant University, Ota, Nigeria.
E-mail: franklyn.ihagwam@covenantuniversity.edu.ng

†Co-first Authors

reported in South American nations [21]. Vaccination has been identified as a critical therapeutic option for eliminating malaria; hence, it is a priority for sustained, substantial, and cost-effective control [22–24]. The only available licensed vaccine against malaria, RTS, S/AS01 shows low to modest efficacy in thwarting malaria caused by *Plasmodium falciparum*, which is enough to prevent clinical malaria but not enough for the global eradication of malaria [1]. Several other vaccines are currently under development, including the R21/Matrix-M (with 77% efficacy in preliminary trials), *P. falciparum* sporozoite, and the self-amplifying RNA vaccine. However, no vaccine with 100% efficacy remains available [25–27].

Post-genomic era vaccine development often involves preliminary computational analysis using bioinformatics tools to predict protective antigens rather than experimental studies with the pathogen, as in conventional vaccinology. Antigen characterization using *in silico* strategies and bioinformatics tools is crucial to the protein-based vaccine design and development [28]. Reverse vaccinology is named so because the vaccine discovery process employs computational methods to analyze genomic data instead of wet lab experimental studies with a pathogen, as with conventional vaccinology [29]. This technique has gained increasing global popularity and usage by research groups in the last 20 years for vetting the whole genome for vaccine antigens against several pathogens including *Leishmania* [30], *Lassa fever* [31], Dengue [32], Schistosomiasis [33], and *P. falciparum* [34], among others. This strategy is effective as it saves cost and time, and decrease the risk of failure compared to conventional vaccinology [35].

The World Health Organization set the goal to eradicate malaria in 1948, and efforts have been intensified to this end. Correspondingly, malaria-related fatalities progressively

decreased, but this progress stalled due to the COVID-19 pandemic and attributed to the interference with malaria services and diagnostic practices [36]. In 2021, the number of malaria cases worldwide was recorded to be 241 million, with 627,000 related deaths [37]. In light of the available data and the current state of global malaria burden, this research aimed to develop a potent multi-epitope blood stage subunit vaccine candidate against *P. falciparum* by integrating epitopes from the most immunogenic regions of three merozoite surface proteins namely, liver-stage antigen 3 (LSA3-C), merozoite surface antigen 180 (MSA 180), and merozoite surface antigen 10 (MSA 10).

METHODOLOGY

A systematic flow chart was followed stepwise to identify immunodominant B- and T-cell epitopes and the design of a subunit vaccine via immunoinformatics techniques. A subsequent biophysical study was performed using integrated docking, immune simulation, and molecular docking. Finally, codon optimization was executed to ensure optimal expression in the microbial host (Fig. 1).

Amino acid sequence retrieval

To retrieve the primary sequence of liver stage antigen 3, MSA 180, and merozoite surface protein 10, the PlasmoDB [38] server was employed. However, only the most immunogenic regions of these proteins—(LSA3-C; V750-K1433), merozoite surface antigen 180 truncate-4 (MSA 180-T4; A805-P1093), and merozoite surface protein 10 region 1 (MSP10 R1; D29-N188) were further exploited for the vaccine construct (VC), following results from prior studies [39–41].




Figure 1. Methodology flow chart showing the step-by-step procedures used.

Forecast of B-cell epitopes

Using default parameters for both, two servers were used to forecast the B-cell epitopes, including ABCpred [42] and BepiPred 2.0 [43]. Matching epitopes forecasted by both servers were selected. Furthermore, finalized epitopes were vetted for antigenicity (VaxiJen 2.0 server) [44], allergenicity (AllergenFP v.1.0) server [45], toxicity (ToxinPred server) [46], and conservancy (Protein Blast - NCBI). For conservancy, the epitopes were screened against *Homo sapiens* proteome (taxid: 9606), with nonhomology indicated by e-value scores ≥ 0.05 [47].

Forecast of CD4+ and CD8+ T-cell epitopes

The NetMHCIIpan 4.0 server [48] was utilized to identify helper T lymphocyte (HTL) epitopes with a threshold of 1% (strong binding) and 5% (weak binding). Twelve major histocompatibility complex (MHC) supertypes available on the NetCTL 1.2 server were screened to predict CD8+ epitopes, with default parameters [49,50]. Also, the predicted epitopes were screened for antigenicity (VaxiJen 2.0 server) and immunogenicity (IEDB server), set at a threshold of 0.4 and default parameters respectively.

Designing of polypeptide subunit vaccine

The finalized B- and T-cell epitopes were integrated using several linkers, including the EAAAK (L1), AAY (L2), GPGPG (L3), and KK (L4) linkers. The adjuvant (ADV) RS09 was included at the N-terminals of the VC and is joined to the CD8+ epitopes by the EAAAK linker. The CD8+ epitopes were intralinked through the AAY linker and interlinked with the CD4+ epitopes by the GPGPG linker, which also intralinks the CD4+ epitopes. KK linkers interlink the CD4+ and B-cell epitopes and intralink the B-cell epitopes. The final VC comprises a His-tag (HHHHHH) at the C-terminal and is arranged ADV-CTL epitopes-HTL epitopes-B-cell epitopes-6X His tag.

Secondary and tertiary structure prediction, evaluation, and validation

Psipred [51] and RaptorX [52] servers were employed to forecast the secondary organization of the multi-epitope construct. Robetta [53], which creates three-dimensional (3D) models by employing ab initio and comparative modeling simulations, was used to predict the constructs' tertiary structure [54]. Pymol 2.5 visualization software was used to envision the protein's 3D organization. Subsequent refinement to improve the 3D model was evaluated using the GalaxyWEB [55] server.

The ProSA-web server [56] and Saves v.6.0 [57] server were employed to ascertain the quality of the 3D models. The Z-scores of each protein solved experimentally using data from X-ray and nuclear magnetic resonance sources are presented in a plot by ProSA. It determines whether the z-score of the 3D model of the query protein falls within the normal range for scores for native proteins of comparable size. The Ramachandran plot examines the model's phi/psi distribution and C-beta deviation to determine the backbone (C-alpha) geometry [58].

Conformational B-cell epitopes

The VCs tertiary structure was put in the Ellipro server, which forecasts and visualizes discontinuous B-cell epitopes [59].

Structural and functional characterization of vaccine construct

The ExpASy-ProtParam tool [60] was used to estimate the physicochemical parameters of the VC. Furthermore, the antigenic and allergenic properties were predicted.

Molecular docking and immune simulation of vaccine construct

Toll-like receptors (TLR)-2 and -4 were selected as effective immunological targets for provoking the innate immune system. The ClusPro 2.0.php server was employed in accessing the interaction between the TLRs (receptor) and VC (ligand) [61,62]. The C-IMMSIM web server, which uses machine learning techniques and a position-specific scoring matrix, was utilized to determine the immune profile of the VC for 3 injections administered 4 weeks apart [63,64]. Default parameters were set with 1, 84, and 170 specified time steps [65].

Molecular dynamics (MD) simulation of vaccine construct-TLR complexes

The iMODS server [66] predicts the MD, which uses the normal mode analysis (NMA) in internal coordinates to delineate the collective protein motions.

Codon optimization and *in silico* cloning of vaccine construct

To forecast a viable option for the expression and isolation of the VC, the JCat server [67] was used to improve the construct's nucleotide sequence to commonly utilized codons of the *Escherichia coli* K 12 strain to enable optimal protein production by the expression host. Also, *in silico* cloning requires the SnapGene software to incorporate restriction sites (EcoRI and BamHI), after which the genetic sequence is integrated into the vector pET-28a(+).

RESULTS AND DISCUSSION

Proteins that encrust the extracellular surface of merozoite and are released from its specialized secretory apical organelles are considered potential vaccine candidates for the erythrocytic stage malaria [68]. Robust experimental evidence supports the importance of these surface proteins to host cell invasion, parasite growth, and survival and as potential preventive measures against *P. falciparum* malaria in humans [11,40,69-75]. In this study, three experimentally validated vaccine candidates against *falciparum* malaria were selected for further downstream immunoinformatics analysis.

The LSA3-C, MSA 180-T4, and MSP10 R1 are regions of blood-stage *P. falciparum* proteins that possess characteristics which have been experimentally validated to be malaria vaccine candidates, and this makes them attractive targets for developing a sub-unit vaccine [39-41]. Liver-stage antigen 3 (PF3D7_0220000) is a ~175kDa protein expressed

in liver and blood stages on sporozoites surface, infected hepatocytes, and blood-stage merozoites, and several research groups have reported it to be a viable pre-erythrocytic and blood stage vaccine target [39,76–78]. Furthermore, LSA3 was reported to be highly conserved following genomic sequence analysis of 20 *P. falciparum* clinical isolates from diverse geographical regions and localized in the parasitophorous vacuole during the ring-stage following merozoite ingress [78,79]. Previous studies on the full-length and discrete regions of LSA3-C have reported its viability as a pre-erythrocytic and blood-stage vaccine candidate in addition to being the most immunologic antigen segment [39,78,79].

Plasmodium falciparum merozoite surface antigen 180 (*Pf*MSA180) is a 170kDa protein that is essential and conserved in all *Plasmodium* sp.; it is expressed on the periphery of merozoites and has been implicated in merozoite ingress and egress during the asexual blood stage of the parasite's lifecycle [41,80]. *Pf*MSA180 (PF3D7_1014100) has been reported to be critical for parasite invasion of the erythrocyte, and antibodies against the C-terminal region of *Pf*MSA180 [MSA 180 Tr-4 (A805-P1093)] abrogated merozoite invasion *in vitro* and conferred protective immunity against malaria [41]. Furthermore, the *Pf*MSA180 (*Pf*MSA180-Tr4) C-terminal region was reported to be highly conserved across isolates, interacts with the red blood cell (RBC) surface protein-CD47, and stimulates antibodies that abrogate parasite invasion; hence, Nagaoka *et al.* [41] proposed MSA 180 Tr-4 as a potential vaccine candidate. *Pf*MSP10 (PF3D7_0620400) is an 80 kDa protein that directly interacts with *Pf*GAMA, which is key for erythrocyte invasion. The *Pf*MSP10 R1 (D29-N188) region was hypothesized to be the interacting region [41]. Also, bioinformatics genome-wide screening has predicted *Pf*MSP10 to be a putative vaccine candidate [81].

Prediction of linear B-cell epitopes

B-cells comprise one of the two main types of cells in the adaptive immune system. Their epitopes are antigenic components, which trigger the synthesis of antibodies [82]. To overcome the challenge of prediction inaccuracy, we employed two servers for better B-cell epitope mapping. The results were compared, and consistent epitopes with both servers were selected. Also, nonantigenic, allergenic, toxic, and conserved epitopes in humans were discriminated against. The top three

epitopes from each vaccine candidate that passed the screening (antigenicity, allergenicity, toxicity, and conservancy) for inclusion in the VC were selected (Table 1) from the epitopes with scores ≥ 0.52 (Table S1).

CD4+ T-cell epitopes prediction

MHC II encrusts the periphery of antigen-presenting cells (APCs). These MHCs exhibit nonself-peptides to helper T-cells, which coordinates other immune responses [83]. Hence, it is essential to predict epitopes with a higher likelihood of being displayed by the MHC-II molecule. Strong interaction between the HTL epitope and HLA-DR is critical for epitope immunogenicity, and excellent HTL epitope candidates are expected to interact optimally with numerous HLA alleles [84,85]. To this end, LSA3-C, MSA-Tr4, and MSP10 R1 were subjected to CD4+ epitope prediction, and only the epitopes that can bind to three or more HLA-DR alleles were agreed upon [86]. The top three epitope sequences for each are included as shown in Tables 2 and S2.

CD8+ T-cell epitopes prediction

APCs and infected RBCs cells display peptides of pathogen origin on MHC I molecules expressed on their surface to cytotoxic T-cells, facilitating clearance and immunological memory [87]. LSA3-C, MSA-Tr4, and MSP10 R1 were screened for their MHC-I epitopes using all 12 MHC-I supertype, available on the NetCTL1.2 server. Table 3 shows the finalized epitopes after the proteins were subjected to further screening parameters, including; antigenicity, allergenicity, immunogenicity, and conservancy predictions.

Polypeptide subunit vaccine design

The finalized B- and T-cell epitopes were integrated using suitable linkers alongside two ADVs. ADVs present a classical approach to targeted delivery of subunit vaccines and maximizing protective immunity, as protein vaccine candidates are poorly immunogenic [88]. They bridge the antigens with the APCs by projecting visibility of the otherwise non or weakly immunogenic antigen to the immune cells to trigger a better immune response [89]. RS09, a synthetic TLR4 agonist comprising seven amino acid residues [89], was incorporated as ADVs at the N-terminal of the VC [90,91]. The EAAAK linker increases

Table 1. Selected linear B-cell epitopes with their antigenicity, allergenicity, toxicity, and conservancy.

Antigen	Epitope	Position	Score	Antigenicity	Allergenicity	Toxicity	Conservancy
LSA 3-C (V750-K1433)	VEHIISGDAHIKGLEE	428	0.92	+	-	-	-
	TESIKDKEKDVSLVVE	209	0.90	+	-	-	-
	TVEISGESLENNEMDK	8	0.89	+	-	-	-
MSA-Tr4 (A805-P1093)	HKDNDSRYTDNSNKNR	35	0.91	+	-	-	-
	TSDILYKDIEENKNT	185	0.88	+	-	-	-
	SKVTGDSVENINEQTN	269	0.85	+	-	-	-
MSP10 R1 (D29-N188)	KITYDKYNKNKENMNN	10	0.87	+	-	-	-
	NKENMNEKNDNKNKDK	19	0.86	+	-	-	-
	NKDNKDNIYNDNINND	30	0.85	+	-	-	-




Figure 3. Schematic diagram of the secondary structure of VC. (A) Predicted secondary structure (H: α -helix, E: β -strand, C: coil) by PSIPRED. The bar chart represents the percentage of confidence. (B) RaptorX generated the chimeric protein's secondary structure, and the results show a structure made up of 26% α -helix, 7% β -strand and 66% coil.

Structural and functional characterization of VC

The physicochemical properties prediction revealed that the protein has a molecular weight and theoretical pI of 49.2 kDa and 5.99, respectively. The half-life was predicted to be 4.4 hours (mammalian reticulocytes, *in vitro*), >20 hours (yeast, *in vivo*), and >10 hours (*Escherichia coli*, *in vivo*). The instability index and GRAVY were forecasted to be 39.36 and -1.294, respectively. The score from the instability index suggested that the protein is stable. The GRAVY score represented that the protein is hydrophilic, which is a desired quality for a vaccine as it indicates the ability to trigger an elevated humoral immune




Figure 4. (A) 3D structure cartoon representation (Red, green, and yellow represent α -helix, coil, and β -sheet). (B) ProSA map of the sub-unit vaccine with Z-score of -7.37. (C) Ramachandran plot before protein refinement with 93.8% in the favored region, 5.2% allowed region, 0.8% in the disallowed region. (D) Ramachandran plot after protein refinement with 95.3% favored region, 3.4% allowed region, and 0.5% disallowed region.




Figure 5. 3-D representation of the four conformational B-cell epitopes. (A–D) A yellow surface represents the epitopes.

response [100]. The aliphatic index was predicted to be 61.40, reflecting thermostability (Table S2).

Molecular docking of vaccine construct with toll-like receptors

The contact between ligand and receptor molecules is embroiled in molecular docking to generate a stable ligand-receptor product [101]. The interaction between antibodies

Table 4. Molecular docking score between VC and TLR-2 and -4.

	Cluster	Members	Representative	Weighted score (kcal/mol)
VC-TLR-2	0	81	Centre	-791.7
			lowest energy	-945.1
VC-TLR-4	0	72	Centre	-796.1
			lowest energy	-919.8

and their targeted antigens is critical to the humoral immune response to aid pathogen elimination. The VC-TLR2 complex has a total of 81 members in its cluster, while VC-TLR4 has 72 members in its cluster. The lowest energy score and binding affinity of -945.1 and -919.8 kcal/mol were obtained for the VC-TLR2 and VC-TLR4 complexes, respectively (Table 4). These complexes were stable as shown in Figure S1.

Immune simulation of vaccine construct

The immune simulation was performed to determine the natural immune response to the VC. The immune simulator C-ImmSim tool was employed to simulate the natural responses formed by the immune system. Figure 6 indicated that the antigenic recognition and desired corresponding immune responses would manifest. There was a marked increase in IgM and IgG production and the expansion of Helper T-cells due to memory development following primary immunization. There was also a depletion in antigen concentration, reflecting a rise in memory B-cell production (Fig. 6A–D). Figure 6F shows an elevation in the concentration of cytotoxic T-cells following vaccine administration. Similarly, there is an increase in the proliferation of cytokines, including IFN- γ , TGF- β , IL-10, and IL-12 (Fig. 6I), indicating that the vaccine is capable of provoking the immune response to act against malaria.

MD simulation of vaccine construct-TLR complexes

MD simulation is useful for analyzing the stability of protein-ligand complex by incorporating Newton's laws of motion [102]. It was done by enumerating protein dynamics to their normal modes using the iMODS server [103]. NMA is commonly used to evaluate the collective functional motions of docked protein-protein complexes [66]. The 3D interaction between VC-TLR2 and VC-TLR4 complexes is presented, with the arrows representing the direction of amino acids (Fig. 7A and B). The peaks on the deformability graph delineate deformability, as higher peaks depict higher deformability. From the result, the deformability plots report the stability of the complexes with individual amino acid residues having a lesser likelihood of deforming (Fig. 7C and D). The B-factor graph comparatively evaluates the NMA and the protein data bank field of the docked complexes (Fig. 7E and F). The eigenvalue corresponds with motion stiffness; a lower value is congruent with higher deformability and vice versa. The predicted high values of $9.12572e^{-07}$ and $1.117255e^{-06}$ for VC-TLR2 and VC-TLR4, respectively, reflect the less deformability and high stability of both complexes (Fig. 7G and H). The variance corresponding to each normal mode is inversely proportional to the eigenvalue




Figure 6. Characterisation of the immune profile of the construct. (A) The antibody production denotes a rise in immune response following the vaccine shot. Antibody subtypes (IgM, IgG1, and IgG2) are depicted as colored peaks. (B) The active B-cell population is observed with the vaccine shots. (C) B-lymphocyte population per entity-state (D) CD4+ T-helper lymphocytes count sub-divided per entity-state (E) The generation of cytotoxic-T cells. (F) CD8+ T-cytotoxic lymphocytes count per entity-state (G) Dendritic cells for MHC class I and II. Shows the total number of active, resting, internalized, and presenting antigen (H) Macrophages. Total count, internalized, presenting on MHC class-II, active and resting macrophages (I) Concentration of cytokines and interleukins.

(Fig. 7I and J) [104]. The covariance matrix reflects if the pairs of residues' motions were correlated (red), uncorrelated (white), or anti-correlated (blue) (Fig. 7K and L). The elastic




Figure 7. (A, B) NMA mobility, (C, D) deformability, (E, F) B factor, (G, H) Eigenvalue, (I, J) variance map, (K, L) Covariance map and (M, N) Elastic network graph of docked complexes VC-TLR2 and VC-TLR4, respectively. For the covariance map, red: correlated, white: uncorrelated and blue: anti-correlated motions, while for the elastic network graph of docked complexes, darker grey regions correlate with stiffer regions. VC: Vaccine construct.




Figure 8. *In silico* cloning of the leading VCs. The red fragment designates the inserted vaccine and the pET-28a(+) vector is presented in a black circle.

network graph reflects atom pairs joined by springs, which are correspondingly colored by the degree of stiffness. The lighter grey area corresponds to less rigid springs and vice versa (Fig. 7M and N).

Codon optimization and *in silico* cloning of VC

Successful cloning and expression of the designed VC are critical for developing a vaccine since a poorly optimized codon could translate to a minimal expression rate in the host. The improved DNAs were 1,311 nucleotides long. A good guanine-cytosine (GC) value ranges between 30 and 70, while the Codon adaptation index (CAI) above 0.5 is good. Our chimeric proteins have good GC and CAI values of 42.94 and 0.99, hinting at a high likelihood of good expression in the prokaryotic host. Finally, the optimized sequence (highlighted in red) was incorporated into the *E. coli* pET-28a(+) vector for optimal gene expression (Fig. 8).

CONCLUSION

A multi-immune inducer that targets several antigens or various points of the parasite's entire life cycle may effectively engender robust clinical protection against malaria. To the best of our knowledge, this is the first study to use short regions rather than full-length proteins of experimentally validated vaccine candidates to contrive an antibody-inducing multi-epitope subunit vaccine targeting the blood stage of *falciparum* malaria. This is important because regions of vaccine candidates that have been experimentally validated to be most immunogenic will be most attractive for mapping immunodominant epitopes capable of being integrated to form a potent subunit vaccine. The VC demonstrated the ability to evoke combined innate and adaptive immune responses via interaction with the TLR-2 and -4, triggering cellular and humoral immunity in addition to forming a stable VC-receptor complex. The limitation of this study is that it is completely performed *in silico*. Therefore, an experimental study is

necessary to determine the full potential of the proposed vaccine as a possible intervention in neutralizing malaria.

ACKNOWLEDGMENT

Covenant Applied Informatics and Communication Africa Centre of Excellence (CApIC-ACE) scholarship to COM is acknowledged. The deference of APC by Covenant University Centre for Research, Innovation and Discovery is appreciated

AUTHOR CONTRIBUTIONS

COM and FNI: Conceptualisation, Simulation, Analysis, Writing the first draft and Approval of Final Copy; EOO: Simulation, Analysis and Approval of Final Copy; TMD and OOO: Supervision, Analysis and Approval of Final Copy.

FINANCIAL SUPPORT

This research did not receive any grant.

CONFLICT OF INTEREST

The authors report there are no competing interests to declare.

ETHICAL APPROVALS

This study does not involve experiments on animals or human subjects.

DATA AVAILABILITY

The authors confirm that data supporting this study finding are available within the article and its supplementary material.

PUBLISHER'S NOTE

This journal remains neutral with regard to jurisdictional claims in published institutional affiliation.

REFERENCES

- Arora N, Anbalagan LC, Pannu AK. Towards eradication of malaria: is the WHO's RTS,S/AS01 vaccination effective enough? Risk Manag Healthc Policy. 2021;14:1033–9. doi: <https://doi.org/10.2147/RMHP.S219294>
- Henry NB, Sermé SS, Siciliano G, Sombié S, Diarra A, Sagnon N, et al. Biology of *Plasmodium falciparum* gametocyte sex ratio and implications in malaria parasite transmission. Malar J. 2019;18:70. doi: <https://doi.org/10.1186/s12936-019-2707-0>
- Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, et al. A molecular marker of artemisinin-resistant *Plasmodium falciparum* malaria. Nature. 2014;505:50–5. doi: <https://doi.org/10.1038/nature12876>
- Adeyemo AO, Aborode AT, Bello MA, Obianuju AF, Hasan MM, Kehinde DO, et al. Malaria vaccine: the lasting solution to malaria burden in Africa. Ann Med Surg. 2022;79:104031. doi: <https://doi.org/10.1016/j.amsu.2022.104031>
- Kanoi BN, Nagaoka H, Morita M, Tsuboi T, Takashima E. Leveraging the wheat germ cell-free protein synthesis system to accelerate malaria vaccine development. Parasitol Int. 2021;80:102224. doi: <https://doi.org/10.1016/j.parint.2020.102224>
- Miquel-Clopés A, Bentley EG, Stewart JP, Carding SR. Mucosal vaccines and technology. Clin Exp Immunol. 2019;196:205–14. doi: <https://doi.org/10.1111/cei.13285>

7. Cantini F, Savino S, Scarselli M, Masignani V, Pizza M, Romagnoli G, *et al.* Solution structure of the immunodominant domain of protective antigen GNA1870 of *Neisseria meningitidis*. *J Biol Chem.* 2006;281:7220–7. doi: <https://doi.org/10.1074/jbc.M508595200>
8. Chaudhuri R, Ahmed S, Ansari FA, Singh HV, Ramachandran S. MalVac: database of malarial vaccine candidates. *Malar J.* 2008;7:184. doi: <https://doi.org/10.1186/1475-2875-7-184>
9. Talukdar S, Zutshi S, Prashanth KS, Saikia KK, Kumar P. Identification of potential vaccine candidates against *Streptococcus pneumoniae* by reverse vaccinology approach. *Appl Biochem Biotechnol.* 2014;172:3026–41. doi: <https://doi.org/10.1007/s12010-014-0749-x>
10. Monterrubio-López GP, González-Y-Merchand JA, Ribas-Aparicio RM. Identification of novel potential vaccine candidates against tuberculosis based on reverse vaccinology. *BioMed Res Int.* 2015;2015:1–16. doi: <https://doi.org/10.1155/2015/483150>
11. Burns AL, Dans MG, Balbin JM, de Koning-Ward TF, Gilson PR, Beeson JG, *et al.* Targeting malaria parasite invasion of red blood cells as an antimalarial strategy. *FEMS Microbiol Rev.* 2019;43:223–38. doi: <https://doi.org/10.1093/femsre/fuz005>
12. Draper SJ, Angov E, Horii T, Miller LH, Srinivasan P, Theisen M, *et al.* Recent advances in recombinant protein-based malaria vaccines. *Vaccine.* 2015;33:7433–43. doi: <https://doi.org/10.1016/j.vaccine.2015.09.093>
13. Ogutu BR, Apollo OJ, McKinney D, Okoth W, Siangla J, Dubovsky F, *et al.* Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. *PLoS One.* 2009;4:e4708. doi: <https://doi.org/10.1371/journal.pone.0004708>
14. Ferreira MU, da Silva Nunes M, Wunderlich G. Antigenic diversity and immune evasion by malaria parasites. *Clin Vaccine Immunol.* 2004;11:987–95. doi: <https://doi.org/10.1128/CDLI.11.6.987-995.2004>
15. Mahajan RC, Farooq U, Dubey ML, Malla N. Genetic polymorphism in *Plasmodium falciparum* vaccine candidate antigens. *Indian J Pathol Microbiol.* 2005;48:429–38.
16. Matuschewski K. Vaccines against malaria—still a long way to go. *FEBS J.* 2017;284:2560–8. doi: <https://doi.org/10.1111/febs.14107>
17. Stipel RT, Batty CJ, MacRaild CA, Norton R, Bachelder E, Ainslie KM. Merozoite surface protein 2 adsorbed onto acetalated dextran microparticles for malaria vaccination. *Int J Pharm.* 2021;593:120168. doi: <https://doi.org/10.1016/j.ijpharm.2020.120168>
18. Takala SL, Coulibaly D, Thera MA, Batchelor AH, Cummings MP, Escalante AA, *et al.* Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development. *Sci Transl Med [Internet].* 2009 [cited 2022 Sep 30];1:2ra5. doi: <https://doi.org/10.1126/scitranslmed.3000257>
19. Frimpong A, Kusi KA, Ofori MF, Ndifon W. Novel strategies for malaria vaccine design. *Front Immunol.* 2018;9:2769. doi: <https://doi.org/10.3389/fimmu.2018.02769>
20. Adedeji EO, Ogunlana OO, Fatumo S, Beder T, Ajamma Y, Koenig R, *et al.* Anopheles metabolic proteins in malaria transmission, prevention and control: a review. *Parasit Vectors.* 2020;13:465. doi: <https://doi.org/10.1186/s13071-020-04342-5>
21. Espinoza J. Malaria resurgence in the Americas: an underestimated threat. *Pathogens.* 2019;8:11. doi: <https://doi.org/10.3390/pathogens8010011>
22. Chandramohan D, Zongo I, Sagara I, Cairns M, Yerbanga RS, Diarra M, *et al.* Seasonal malaria vaccination with or without seasonal malaria chemoprevention. *N Engl J Med.* 2021;385:1005–17. doi: <https://doi.org/10.1056/NEJMoa2026330>
23. Penny MA, Verity R, Bever CA, Sauboin C, Galactionova K, Flasche S, *et al.* Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models. *Lancet.* 2016;387:367–75. doi: [https://doi.org/10.1016/S0140-6736\(15\)00725-4](https://doi.org/10.1016/S0140-6736(15)00725-4)
24. World Health Organization. World malaria report 2019 [Internet]. Geneva, Switzerland: World Health Organization; 2019 [cited 2022 Sep 23]. Available from: <https://apps.who.int/iris/handle/10665/330011>
25. Coulibaly D, Kone AK, Traore K, Niangaly A, Kouriba B, Arama C, *et al.* PfSPZ-CVac malaria vaccine demonstrates safety among malaria-experienced adults: a randomized, controlled phase 1 trial. *EClinicalMedicine.* 2022;52:101579. doi: <https://doi.org/10.1016/j.eclinm.2022.101579>
26. Dattoo MS, Natama HM, Somé A, Bellamy D, Traoré O, Rouamba T, *et al.* Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial. *Lancet Infect Dis.* 2022;22(12):1728–36. doi: [https://doi.org/10.1016/S1473-3099\(22\)00442-X](https://doi.org/10.1016/S1473-3099(22)00442-X)
27. Hussain A, Yang H, Zhang M, Liu Q, Alotaibi G, Irfan M, *et al.* mRNA vaccines for COVID-19 and diverse diseases. *J Controlled Release.* 2022;345:314–33. doi: <https://doi.org/10.1016/j.jconrel.2022.03.032>
28. Martinelli DD. *In silico* vaccine design: a tutorial in immunoinformatics. *Healthc Anal.* 2022;2:100044. doi: <https://doi.org/10.1016/j.health.2022.100044>
29. Rappuoli R. Reverse vaccinology. *Curr Opin Microbiol.* 2000;3:445–50. doi: [https://doi.org/10.1016/S1369-5274\(00\)00119-3](https://doi.org/10.1016/S1369-5274(00)00119-3)
30. Vakili B, Eslami M, Hatam GR, Zare B, Erfani N, Nezafat N, *et al.* Immunoinformatics-aided design of a potential multi-epitope peptide vaccine against *Leishmania infantum*. *Int J Biol Macromol.* 2018;120:1127–39. doi: <https://doi.org/10.1016/j.ijbiomac.2018.08.125>
31. Sayed SB, Khan Z, Khan MSA, Abdulla F, Tasmin R, Adhikari UK. Exploring Lassa virus proteome to design a multi-epitope vaccine through immunoinformatics and immune simulation analyses. *Int J Pept Res Ther.* 2020;26:2089–107. doi: <https://doi.org/10.1007/s10989-019-10003-8>
32. Ali M, Pandey RK, Khatoun N, Narula A, Mishra A, Prajapati VK. Exploring dengue genome to construct a multi-epitope based subunit vaccine by utilizing immunoinformatics approach to battle against dengue infection. *Sci Rep.* 2017;7:9232. doi: <https://doi.org/10.1038/s41598-017-09199-w>
33. Rahmani A, Bae M, Rostamtabar M, Karkhah A, Alizadeh S, Tourani M, *et al.* Development of a conserved chimeric vaccine based on helper T-cell and CTL epitopes for induction of strong immune response against *Schistosoma mansoni* using immunoinformatics approaches. *Int J Biol Macromol.* 2019;141:125–36. doi: <https://doi.org/10.1016/j.ijbiomac.2019.08.259>
34. Pritam M, Singh G, Swaroop S, Singh AK, Singh SP. Exploitation of reverse vaccinology and immunoinformatics as promising platform for genome-wide screening of new effective vaccine candidates against *Plasmodium falciparum*. *BMC Bioinform.* 2019;19:468. doi: <https://doi.org/10.1186/s12859-018-2482-x>
35. Pritam M, Singh G, Swaroop S, Singh AK, Pandey B, Singh SP. A cutting-edge immunoinformatics approach for design of multi-epitope oral vaccine against dreadful human malaria. *Int J Biol Macromol.* 2020;158:159–79. doi: <https://doi.org/10.1016/j.ijbiomac.2020.04.191>
36. Albrecht-Schgoer K, Lackner P, Schmutzhard E, Baier G. Cerebral malaria: current clinical and immunological aspects. *Front Immunol.* 2022;13:863568. doi: <https://doi.org/10.3389/fimmu.2022.863568>
37. World Health Organization. World malaria report 2021 [Internet]. Geneva, Switzerland: World Health Organization; 2021 [cited 2022 Sep 23]. Available from: <https://apps.who.int/iris/handle/10665/350147>
38. Bahl A. PlasmoDB: the *Plasmodium* genome resource. A database integrating experimental and computational data. *Nucleic Acids Res.* 2003;31:212–5. doi: <https://doi.org/10.1093/nar/gkg081>
39. Morita M, Takashima E, Ito D, Miura K, Thongkukiatkul A, Diouf A, *et al.* Immunoscreening of *Plasmodium falciparum* proteins

- expressed in a wheat germ cell-free system reveals a novel malaria vaccine candidate. *Sci Rep.* 2017;7:46086. doi: <https://doi.org/10.1038/srep46086>
40. Nagaoka H, Kanoi BN, Jinoka K, Morita M, Arumugam TU, Palacpac NMQ, *et al.* The N-terminal region of *Plasmodium falciparum* MSP10 is a target of protective antibodies in malaria and is important for PfGAMA/PfMSP10 interaction. *Front Immunol.* 2019;10:2669. doi: <https://doi.org/10.3389/fimmu.2019.02669>
 41. Nagaoka H, Sasaoka C, Yuguchi T, Kanoi BN, Ito D, Morita M, *et al.* PfMSA180 is a novel *Plasmodium falciparum* vaccine antigen that interacts with human erythrocyte integrin associated protein (CD47). *Sci Rep.* 2019;9:5923. doi: <https://doi.org/10.1038/s41598-019-42366-9>
 42. Saha S, Raghava GPS. Prediction of continuous B-cell epitopes in an antigen using recurrent neural network. *Proteins Struct Funct Bioinform.* 2006;65:40–8. doi: <https://doi.org/10.1002/prot.21078>
 43. Jespersen MC, Peters B, Nielsen M, Marcatili P. BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes. *Nucleic Acids Res.* 2017;45:W24–9. doi: <https://doi.org/10.1093/nar/gkx346>
 44. Doytchinova IA, Flower DR. VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. *BMC Bioinform.* 2007;8:4. doi: <https://doi.org/10.1186/1471-2105-8-4>
 45. Dimitrov I, Naneva L, Doytchinova I, Bangov I. AllergenFP: allergenicity prediction by descriptor fingerprints. *Bioinformatics.* 2014;30:846–51. doi: <https://doi.org/10.1093/bioinformatics/btt619>
 46. Gupta A, Mir SS, Saqib U, Biswas S, Vaishya S, Srivastava K, *et al.* The effect of fusidic acid on *Plasmodium falciparum* elongation factor G (EF-G). *Mol Biochem Parasitol.* 2013;192:39–48. doi: <https://doi.org/10.1016/j.molbiopara.2013.10.003>
 47. Mehla K, Ramana J. Identification of epitope-based peptide vaccine candidates against enterotoxigenic *Escherichia coli*: a comparative genomics and immunoinformatics approach. *Mol Biosyst.* 2016;12:890–901. doi: <https://doi.org/10.1039/C5MB00745G>
 48. Reynisson B, Alvarez B, Paul S, Peters B, Nielsen M. NetMHCpan-4.0 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. *Nucleic Acids Res.* 2021;49:W449–54. doi: <https://doi.org/10.1093/nar/gkaa379>
 49. Alam A, Khan A, Imam N, Siddiqui MF, Waseem M, Malik MZ, *et al.* Design of an epitope-based peptide vaccine against the SARS-CoV-2: a vaccine-informatics approach. *Brief Bioinform.* 2021;22:1309–23. doi: <https://doi.org/10.1093/bib/bbaa340>
 50. Larsen MV, Lundegaard C, Lamberth K, Buus S, Lund O, Nielsen M. Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction. *BMC Bioinform.* 2007;8:424. doi: <https://doi.org/10.1186/1471-2105-8-424>
 51. McGuffin LJ, Bryson K, Jones DT. The PSIPRED protein structure prediction server. *Bioinformatics.* 2000;16:404–5. doi: <https://doi.org/10.1093/bioinformatics/16.4.404>
 52. Källberg M, Wang H, Wang S, Peng J, Wang Z, Lu H, *et al.* Template-based protein structure modeling using the RaptorX web server. *Nat Protoc.* 2012;7:1511–22. doi: <https://doi.org/10.1038/nprot.2012.085>
 53. Raman S, Vernon R, Thompson J, Tyka M, Sadreyev R, Pei J, *et al.* Structure prediction for CASP8 with all-atom refinement using Rosetta. *Proteins Struct Funct Bioinform.* 2009;77:89–99. doi: <https://doi.org/10.1002/prot.22540>
 54. Rodrigues-da-Silva RN, Martins da Silva JH, Singh B, Jiang J, Meyer EVS, Santos F, *et al.* *In silico* identification and validation of a linear and naturally immunogenic B-cell epitope of the *Plasmodium vivax* malaria vaccine candidate merozoite surface protein-9. *PLoS One.* 2016;11:e0146951. doi: <https://doi.org/10.1371/journal.pone.0146951>
 55. Ko J, Park H, Heo L, Seok C. GalaxyWEB server for protein structure prediction and refinement. *Nucleic Acids Res.* 2012;40:W294–7. doi: <https://doi.org/10.1093/nar/gks493>
 56. Wiederstein M, Sippl MJ. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. *Nucleic Acids Res.* 2007;35:W407–10. doi: <https://doi.org/10.1093/nar/gkm290>
 57. Colovos C, Yeates TO. Verification of protein structures: patterns of nonbonded atomic interactions. *Protein Sci.* 1993;2:1511–9. doi: <https://doi.org/10.1002/pro.5560020916>
 58. Iheagwam FN, Ogunlana OO, Chinedu SN. Model optimization and *in silico* analysis of potential dipeptidyl peptidase IV antagonists from GC-MS identified compounds in *Nauclea latifolia* leaf extracts. *Int J Mol Sci.* 2019;20:5913. doi: <https://doi.org/10.3390/ijms20235913>
 59. Ponomarenko J, Bui HH, Li W, Fussedner N, Bourne PE, Sette A, *et al.* ElliPro: a new structure-based tool for the prediction of antibody epitopes. *BMC Bioinform.* 2008;9:514. doi: <https://doi.org/10.1186/1471-2105-9-514>
 60. Gasteiger E, Hoogland C, Gattiker A, Duvaud S, Wilkins MR, Appel RD, *et al.* Protein identification and analysis tools on the ExPASy server. In: Walker JM, editor. *The proteomics protocols handbook* [Internet]. Totowa, NJ: Humana Press; 2005 [cited 2022 Oct 1]. pp. 571–607. Available from: <http://link.springer.com/10.1385/1-59259-890-0:571>
 61. Kozakov D, Hall DR, Xia B, Porter KA, Padhorna D, Yueh C, *et al.* The ClusPro web server for protein–protein docking. *Nat Protoc.* 2017;12:255–78. doi: <https://doi.org/10.1038/nprot.2016.169>
 62. Kozakov D, Beglov D, Bohnuud T, Mottarella SE, Xia B, Hall DR, *et al.* How good is automated protein docking?: automated protein docking. *Proteins Struct Funct Bioinform.* 2013;81:2159–66. doi: <https://doi.org/10.1002/prot.24403>
 63. Rapin N, Lund O, Castiglione F. Immune system simulation online. *Bioinformatics.* 2011;27:2013–4. doi: <https://doi.org/10.1093/bioinformatics/btr335>
 64. Rapin N, Lund O, Bernaschi M, Castiglione F. Computational immunology meets bioinformatics: the use of prediction tools for molecular binding in the simulation of the immune system. *PLoS One.* 2010;5:e9862. doi: <https://doi.org/10.1371/journal.pone.0009862>
 65. Sarkar B, Ullah MA, Araf Y, Rahman MS. Engineering a novel subunit vaccine against SARS-CoV-2 by exploring immunoinformatics approach. *Inform Med Unlocked.* 2020;21:100478. doi: <https://doi.org/10.1016/j.imu.2020.100478>
 66. López-Blanco JR, Aliaga JI, Quintana-Ortí ES, Chacón P. iMODS: internal coordinates normal mode analysis server. *Nucleic Acids Res.* 2014;42:W271–6. doi: <https://doi.org/10.1093/nar/gku339>
 67. Grote A, Hiller K, Scheer M, Munch R, Nortemann B, Hempel DC, *et al.* JCat: a novel tool to adapt codon usage of a target gene to its potential expression host. *Nucleic Acids Res.* 2005;33:W526–31. doi: <https://doi.org/10.1093/nar/gki376>
 68. Ito D, Takashima E, Yamasaki T, Hatano S, Hasegawa T, Miura K, *et al.* Antibodies against a *Plasmodium falciparum* RON12 inhibit merozoite invasion into erythrocytes. *Parasitol Int.* 2019;68:87–91. doi: <https://doi.org/10.1016/j.parint.2018.10.006>
 69. Amlabu E, Mensah-Brown H, Nyarko PB, Akuh O, Opoku G, Ilani P, *et al.* Functional characterization of *Plasmodium falciparum* surface-related antigen as a potential blood-stage vaccine target. *J Infect Dis.* 2018;218:778–90. doi: <https://doi.org/10.1093/infdis/jiy222>
 70. Arumugam TU, Takeo S, Yamasaki T, Thonkukiakul A, Miura K, Otsuki H, *et al.* Discovery of GAMA, a *Plasmodium falciparum* merozoite micronemal protein, as a novel blood-stage vaccine candidate antigen. *Infect Immun.* 2011;79:4523–32. doi: <https://doi.org/10.1128/IAI.05412-11>
 71. Garcia-Senosian A, Kana IH, Singh SK, Chourasia BK, Das MK, Dodoo D, *et al.* Peripheral merozoite surface proteins are targets of naturally acquired immunity against malaria in both India and Ghana. *Infect Immun.* 2020;88:e00778–19. doi: <https://doi.org/10.1128/IAI.00778-19>
 72. Nagaoka H, Kanoi BN, Ntege EH, Aoki M, Fukushima A, Tsuboi T, *et al.* Antibodies against a short region of PfRipr inhibit *Plasmodium*

- falciparum* merozoite invasion and PfRipr interaction with Rh5 and SEMA7A. Sci Rep. 2020;10:6573. doi: <https://doi.org/10.1038/s41598-020-63611-6>
73. Patel SD, Ahouidi AD, Bei AK, Dieye TN, Mboup S, Harrison SC, et al. *Plasmodium falciparum* merozoite surface antigen, PFRH5, elicits detectable levels of invasion-inhibiting antibodies in humans. J Infect Dis. 2013;208:1679–87. doi: <https://doi.org/10.1093/infdis/jit385>
 74. Richards JS, Arumugam TU, Reiling L, Healer J, Hodder AN, Fowkes FJL, et al. Identification and prioritization of merozoite antigens as targets of protective human immunity to *Plasmodium falciparum* malaria for vaccine and biomarker development. J Immunol. 2013;191:795–809. doi: <https://doi.org/10.4049/jimmunol.1300778>
 75. Roussillon C, Oeuvray C, Müller-Graf C, Tall A, Rogier C, Trape JF, et al. Long-term clinical protection from *falciparum* malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. PLoS Med. 2007;4:e320. doi: <https://doi.org/10.1371/journal.pmed.0040320>
 76. Daubersies P, Thomas AW, Millet P, Brahimi K, Langermans JAM, Ollomo B, et al. Protection against *Plasmodium falciparum* malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3. Nat Med. 2000;6:1258–63. doi: <https://doi.org/10.1038/81366>
 77. Ghosh S, Chamat S, Prieur E, Stephan A, Druilhe P, Bouharoun-Tayoun H. Evaluating human immune responses for vaccine development in a novel human spleen cell-engrafted NOD-SCID-IL2ryNull mouse model. Front Immunol. 2018;9:601. doi: <https://doi.org/10.3389/fimmu.2018.00601>
 78. Toure-Balde A, Perlaza BL, Sauzet JP, Ndiaye M, Aribot G, Tall A, et al. Evidence for multiple B- and T-cell epitopes in *Plasmodium falciparum* liver-stage antigen 3. Infect Immun. 2009;77:1189–96. doi: <https://doi.org/10.1128/IAI.00780-07>
 79. Prieur E, Druilhe P. The malaria candidate vaccine liver stage antigen-3 is highly conserved in *Plasmodium falciparum* isolates from diverse geographical areas. Malar J. 2009;8:247. doi: <https://doi.org/10.1186/1475-2875-8-247>
 80. Bahl V, Chaddha K, Mian SY, Holder AA, Knepper E, Gaur D. Genetic disruption of *Plasmodium falciparum* merozoite surface antigen 180 (PfMSA180) suggests an essential role during parasite egress from erythrocytes. Sci Rep. 2021;11:19183. doi: <https://doi.org/10.1038/s41598-021-98707-0>
 81. Singh SP, Srivastava D, Mishra BN. Genome-wide identification of novel vaccine candidates for *Plasmodium falciparum* malaria using integrative bioinformatics approaches. 3 Biotech. 2017;7:318. doi: <https://doi.org/10.1007/s13205-017-0947-7>
 82. Silveira ELV, Dominguez MR, Soares IS. To B or not to B: understanding B cell responses in the development of malaria infection. Front Immunol. 2018;9:2961. doi: <https://doi.org/10.3389/fimmu.2018.02961>
 83. Jensen KK, Andreatta M, Marcatili P, Buus S, Greenbaum JA, Yan Z, et al. Improved methods for predicting peptide binding affinity to MHC class II molecules. Immunology. 2018;154:394–406. doi: <https://doi.org/10.1111/imm.12889>
 84. Lata KS, Kumar S, Vagharia V, Sharma P, Bhairappanvar SB, Soni S, et al. Exploring Leptospiral proteomes to identify potential candidates for vaccine design against leptospirosis using an immunoinformatics approach. Sci Rep. 2018;8:6935. doi: <https://doi.org/10.1038/s41598-018-25281-3>
 85. Weber CA, Mehta PJ, Ardito M, Moise L, Martin B, De Groot AS. T cell epitope: friend or foe? Immunogenicity of biologics in context. Adv Drug Deliv Rev. 2009;61:965–76. doi: <https://doi.org/10.1016/j.addr.2009.07.001>
 86. Bemani P, Amirghofran Z, Mohammadi M. Designing a multi-epitope vaccine against blood-stage of *Plasmodium falciparum* by *in silico* approaches. J Mol Graph Model. 2020;99:107645. doi: <https://doi.org/10.1016/j.jmgm.2020.107645>
 87. Kurup SP, Butler NS, Harty JT. T cell-mediated immunity to malaria. Nat Rev Immunol. 2019;19:457–71. doi: <https://doi.org/10.1038/s41577-019-0158-z>
 88. Bonam SR, Rénia L, Tadepalli G, Bayry J, Kumar HMS. *Plasmodium falciparum* malaria vaccines and vaccine adjuvants. Vaccines. 2021;9:1072. doi: <https://doi.org/10.3390/vaccines9101072>
 89. Shanmugam A, Rajoria S, George AL, Mittelman A, Suriano R, Tiwari RK. Synthetic toll like receptor-4 (TLR-4) agonist peptides as a novel class of adjuvants. PLoS One. 2012;7:e30839. doi: <https://doi.org/10.1371/journal.pone.0030839>
 90. Pandey RK, Bhatt TK, Prajapati VK. Novel immunoinformatics approaches to design multi-epitope subunit vaccine for malaria by investigating anopheles salivary protein. Sci Rep. 2018;8:1125. doi: <https://doi.org/10.1038/s41598-018-19456-1>
 91. Maharaj L, Adeleke VT, Fatoba AJ, Adeniyi AA, Tshilwane SI, Adeleke MA, et al. Immunoinformatics approach for multi-epitope vaccine design against *P. falciparum* malaria. Infect Genet Evol. 2021;92:104875. doi: <https://doi.org/10.1016/j.meegid.2021.104875>
 92. Aldakheel FM, Abrar A, Munir S, Aslam S, Allemailem KS, Khurshid M, et al. Proteome-wide mapping and reverse vaccinology approaches to design a multi-epitope vaccine against *Clostridium perfringens*. Vaccines. 2021;9:1079. doi: <https://doi.org/10.3390/vaccines9101079>
 93. Singh H, Jakhar R, Sehrawat N. Designing spike protein (S-Protein) based multi-epitope peptide vaccine against SARS COVID-19 by immunoinformatics. Heliyon. 2020;6:e05528. doi: <https://doi.org/10.1016/j.heliyon.2020.e05528>
 94. Khan SN, Ali R, Khan S, Rooman M, Norin S, Zareen S, et al. Genetic diversity of polymorphic marker merozoite surface protein 1 (Msp-1) and 2 (Msp-2) genes of *Plasmodium falciparum* isolates from malaria endemic region of Pakistan. Front Genet. 2021;12:751552. doi: <https://doi.org/10.3389/fgene.2021.751552>
 95. Ashgar SS, Faidah H, Bantun F, Jalal NA, Qusty NF, Darwish A, et al. Integrated immunoinformatics and subtractive proteomics approach for multi-epitope vaccine designing to combat *S. pneumoniae* TIGR4. Front Mol Biosci. 2023;10:1212119. doi: <https://doi.org/10.3389/fmolb.2023.1212119>
 96. Zhang NZ, Huang SY, Zhou DH, Xu Y, He JJ, Zhu XQ. Identification and bioinformatic analysis of a putative calcium-dependent protein kinase (CDPK6) from *Toxoplasma gondii*. Genet Mol Res GMR. 2014;13:10669–77. doi: <https://doi.org/10.4238/2014>
 97. Khatoun N, Pandey RK, Prajapati VK. Exploring *Leishmania* secretory proteins to design B and T cell multi-epitope subunit vaccine using immunoinformatics approach. Sci Rep. 2017;7:8285. doi: <https://doi.org/10.1038/s41598-017-08842-w>
 98. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr. 1993;26:283–91. doi: <https://doi.org/10.1107/S0021889892009944>
 99. Ferdous S, Kelm S, Baker TS, Shi J, Martin ACR. B-cell epitopes: discontinuity and conformational analysis. Mol Immunol. 2019;114:643–50. doi: <https://doi.org/10.1016/j.molimm.2019.09.014>
 100. Solanki V, Tiwari M, Tiwari V. Prioritization of potential vaccine targets using comparative proteomics and designing of the chimeric multi-epitope vaccine against *Pseudomonas aeruginosa*. Sci Rep. 2019;9:5240. doi: <https://doi.org/10.1038/s41598-019-41496-4>
 101. Iheagwam FN, Israel EN, Kayode KO, De Campos OC, Ogunlana OO, Chinedu SN. GC-MS analysis and inhibitory evaluation of *Terminalia catappa* leaf extracts on major enzymes linked to diabetes. Evid Based Complement Alternat Med. 2019;2019:6316231. doi: <https://doi.org/10.1155/2019/6316231>
 102. Onile OS, Musaigwa F, Ayawei N, Omoboyede V, Onile TA, Oghenevovwero E, et al. Immunoinformatics studies and design of a potential multi-epitope peptide vaccine to combat the fatal visceral

- leishmaniasis. *Vaccines*. 2022;10:1598. doi: <https://doi.org/10.3390/vaccines10101598>
103. Van Aalten DMF, De Groot BL, Findlay JBC, Berendsen HJC, Amadei A. A comparison of techniques for calculating protein essential dynamics. *J Comput Chem*. 1997;18:169–81. doi: [https://doi.org/10.1002/\(SICI\)1096-987X\(19970130\)18:2<169::AID-JCC3>3.0.CO;2-T](https://doi.org/10.1002/(SICI)1096-987X(19970130)18:2<169::AID-JCC3>3.0.CO;2-T).
104. Kovacs JA, Chacón P, Abagyan R. Predictions of protein flexibility: first-order measures. *Proteins Struct Funct Bioinform*. 2004;56:661–8. doi: <https://doi.org/10.1002/prot.20151>

How to cite this article:

Mamudu CO, Iheagwam FN, Okafor EO, Dokunmu TM, Ogunlana OO. Contriving a novel multi-epitope subunit vaccine from *Plasmodium falciparum* vaccine candidates against malaria. *J Appl Pharm Sci*. 2024. <http://doi.org/10.7324/JAPS.2024.162649>

SUPPLEMENTARY MATERIAL

Supplementary data can be downloaded from the journal's website link: [https://japsonline.com/admin/php/uploadss/4324_pdf.pdf]

Online First